Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-02T21:01:17.264Z.
Consensus retrieved: 2026-10-02T16:42:47.886Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T21:01:17.264Z.
Quote observation: 2026-10-02T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a657154a9f7069a814e614f1a1966cdf7daff9b6ba37dfb31f5c5dfa38f3f665
Forward PE Ratio (N/A) = Dated Quote Price ($55.43) / Consensus Forward EPS ($-4.38)
FORWARD PE RATIO
N/A
CRISPR Therapeutics AG
Market Cap
$5.35B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.35B | N/A |
| Doximity, Inc. (DOCS)vs › | $5.22B | 20.73 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 19.84 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | N/A |
| Chemed Corporation (CHE)vs › | $6.63B | 19.91 |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 54.40 |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | 16.21 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $55.43, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.38 | $-5.51 – $-3.32 | 15 | n/m |
| 2027-12-31 | $-3.29 | $-4.92 – $-1.07 | 15 | n/m |
| 2028-12-31 | $-2.00 | $-7.26 – $9.86 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
